Analysts Set Roivant Sciences Ltd. (NASDAQ:ROIV) Price Target at $16.90

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have been assigned an average recommendation of “Moderate Buy” from the ten brokerages that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $16.90.

A number of equities research analysts have commented on the company. Piper Sandler assumed coverage on Roivant Sciences in a research report on Friday, January 5th. They issued an “overweight” rating and a $20.00 target price on the stock. Wolfe Research initiated coverage on Roivant Sciences in a research note on Thursday, February 15th. They issued an “outperform” rating and a $17.00 price objective for the company. The Goldman Sachs Group boosted their target price on Roivant Sciences from $16.00 to $18.00 and gave the stock a “buy” rating in a research note on Wednesday, April 3rd. Truist Financial reissued a “buy” rating and set a $23.00 target price on shares of Roivant Sciences in a research note on Monday, March 25th. Finally, HC Wainwright reissued a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a research note on Monday, April 22nd.

Insider Buying and Selling

In other Roivant Sciences news, COO Eric Venker sold 96,950 shares of the stock in a transaction on Friday, February 9th. The stock was sold at an average price of $10.92, for a total transaction of $1,058,694.00. Following the sale, the chief operating officer now owns 532,207 shares in the company, valued at approximately $5,811,700.44. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 4.60% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Retirement Systems of Alabama purchased a new position in shares of Roivant Sciences in the 1st quarter worth $4,464,000. Privium Fund Management B.V. raised its position in Roivant Sciences by 104.4% in the first quarter. Privium Fund Management B.V. now owns 567,795 shares of the company’s stock valued at $5,985,000 after purchasing an additional 290,000 shares during the period. Principal Financial Group Inc. raised its position in Roivant Sciences by 3,413.9% in the first quarter. Principal Financial Group Inc. now owns 1,274,737 shares of the company’s stock valued at $13,436,000 after purchasing an additional 1,238,460 shares during the period. China Universal Asset Management Co. Ltd. raised its position in Roivant Sciences by 66.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 154,910 shares of the company’s stock valued at $1,633,000 after purchasing an additional 61,921 shares during the period. Finally, Securian Asset Management Inc. purchased a new position in Roivant Sciences in the first quarter valued at about $293,000. Hedge funds and other institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Performance

NASDAQ ROIV opened at $10.90 on Friday. The company has a market cap of $8.78 billion, a PE ratio of 2.10 and a beta of 1.34. The stock’s 50 day simple moving average is $10.90 and its 200-day simple moving average is $10.38. Roivant Sciences has a 1-year low of $8.06 and a 1-year high of $13.24. The company has a debt-to-equity ratio of 0.06, a current ratio of 27.79 and a quick ratio of 27.79.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings data on Tuesday, February 13th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.07. Roivant Sciences had a negative return on equity of 33.38% and a net margin of 3,624.14%. The firm had revenue of $37.14 million for the quarter, compared to the consensus estimate of $30.72 million. As a group, equities research analysts anticipate that Roivant Sciences will post -1.36 EPS for the current fiscal year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.